Home › Companies › Tarsus Pharmaceuticals, Inc. › 2025-2026

Tarsus Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Tarsus Pharmaceuticals, Inc.’s Form 8-K, filed 2026-06-29 (Item 5.07 on EDGAR). Page generated 02 October 2026.

6Reported items
292Asset managers
1,845Fund votes
2026-06-25Meeting date

Proxy season: 2024-2025 2025-2026

Explore Tarsus Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Tarsus Pharmaceuticals, Inc.

These tallies are Tarsus Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-29 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Tarsus Pharmaceuticals, Inc. — official shareholder meeting results, meeting held 2026-06-25
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Wendy Yarno, MBA	34,398,690	--	--	374,956	3,463,568	Majority: yes
Elect Director: Andrew Goldberg, M.D.	26,733,789	--	--	8,039,857	3,463,568	Majority: yes
Elect Director: Scott Morrison	34,225,471	--	--	548,175	3,463,568	Majority: yes
Elect Director: David E.I. Pyott, MBA	33,612,963	--	--	1,160,683	3,463,568	Majority: yes
The following directors, in addition to Ms. Yarno, Dr.	34,486,767	238,014	48,865	--	3,463,568	Majority: yes
Proposal 3: Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm The Company's stockholders approved the ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting	38,219,521	3,651	14,042	--	--	Majority: yes

Source: Tarsus Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-06-29 — read the filing on EDGAR.

How asset managers voted at the Tarsus Pharmaceuticals, Inc. 2025-2026 meeting

Each item below shows how the 292 asset managers that disclosed a Tarsus Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Tarsus Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To hold an advisory vote to approve, on a non-binding basis, our named executive officer compensation.

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

99.6% fund support · no official result

FOR 99.5%

The 288 asset managers below cast 99.6% of the shares they voted on this item FOR (42,163,127 for, 127,984 against).

FOR: 42,163,127 (99.6%)AGAINST: 127,984 (0.3%)ABSTAIN: 58,205 (0.1%)NOT VOTED: 180 (0.0%)

Largest asset managers voting on “To hold an advisory vote to approve, on a non-binding basis, our named executive officer compensation.” at Tarsus Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Janus Henderson	4,604,707	0	For
Deep Track Capital, LP	3,557,678	0	For
RTW INVESTMENTS, LP	3,346,025	0	For
BlackRock	2,962,742	195	For
Vanguard	2,426,512	0	For
Invesco	2,107,425	0	For
Fidelity	2,008,430	0	For
Paradigm Biocapital Advisors LP	2,002,080	0	For
JENNISON ASSOCIATES LLC	1,399,098	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,025,721	0	For
State Street	853,575	1,255	For
Prudential/PGIM	771,839	0	For
JANUS INVESTMENT FUND	738,221	0	For
Frazier Life Sciences Management, L.P.	728,644	0	For
LORD, ABBETT & CO. LLC	685,216	0	For
Charles Schwab	659,123	0	For
Loomis Sayles	616,297	0	For
Clearbridge Investments, LLC	543,961	0	For
Lord Abbett	504,366	0	For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST	499,306	0	For
DRIEHAUS CAPITAL MANAGEMENT LLC	493,320	0	For
T. Rowe Price	489,088	0	For
Legg Mason	443,209	0	For
Putnam	359,526	0	For
TimesSquare Capital Management, LLC	356,340	0	For

Showing the 25 largest of 288 asset managers. See all 288 in the interactive database.

2. To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed: Andrew Goldberg

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD 23%

FOR: 26,733,789WITHHELD: 8,039,857

Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Andrew Goldberg, M.D.”): 26,733,789 for, 8,039,857 withheld, per its Form 8-K filed 2026-06-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,021,312 outstanding shares: 62% for, 19% withheld (81% of the company cast a for/withheld vote).

The 86 asset managers below cast 100% of the shares they voted on this item FOR (9,333,289 for, 0 against).

FOR 81%ABSTAIN 19%

FOR: 9,333,289 (80.7%)ABSTAIN: 2,236,602 (19.3%)

Largest asset managers voting on “To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective” at Tarsus Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	2,084,408	23,267	For
BlackRock	1,588,579	0	For
Fidelity	1,286,608	18,000	For
Prudential/PGIM	667,367	98,272	For
JANUS INVESTMENT FUND	738,221	0	For
Lord Abbett	504,366	0	For
Legg Mason	443,209	0	For
Invesco	441,422	0	For
Charles Schwab	329,520	0	For
Waddell & Reed	0	273,131	Abstain
TIAA	267,608	0	For
MFS	0	261,461	Abstain
Loomis Sayles	0	222,303	Abstain
T. Rowe Price	180,401	0	For
DRIEHAUS MUTUAL FUNDS	0	174,580	Abstain
Putnam	147,318	0	For
Allspring	0	120,498	Abstain
Equitable	91,148	25,540	For
First Trust	0	110,377	Abstain
Delaware/Macquarie	0	100,000	Abstain
State Street	97,305	65	For
Bridge Builder Trust	34,384	55,134	Abstain
MoA Funds Corp	0	67,022	Abstain
QUANTITATIVE MASTER SERIES LLC	64,885	0	For
Brighthouse	0	62,395	Abstain

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

3. To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed: David E.I. Pyott

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 33,612,963WITHHELD: 1,160,683

Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David E.I. Pyott, MBA”): 33,612,963 for, 1,160,683 withheld, per its Form 8-K filed 2026-06-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,021,312 outstanding shares: 78% for, 3% withheld (81% of the company cast a for/withheld vote).

The 86 asset managers below cast 100% of the shares they voted on this item FOR (10,693,047 for, 0 against).

FOR 92%8%

FOR: 10,693,047 (92.4%)ABSTAIN: 876,843 (7.6%)

Largest asset managers voting on “To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective” at Tarsus Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	2,107,672	3	For
BlackRock	1,588,579	0	For
Fidelity	1,304,608	0	For
Prudential/PGIM	765,639	0	For
JANUS INVESTMENT FUND	738,221	0	For
Lord Abbett	504,366	0	For
Legg Mason	443,209	0	For
Invesco	441,422	0	For
Charles Schwab	329,520	0	For
Waddell & Reed	0	273,131	Abstain
TIAA	267,608	0	For
MFS	261,461	0	For
Loomis Sayles	0	222,303	Abstain
T. Rowe Price	180,401	0	For
DRIEHAUS MUTUAL FUNDS	174,580	0	For
Putnam	10,117	137,201	Abstain
Allspring	120,498	0	For
Equitable	116,688	0	For
First Trust	110,377	0	For
Delaware/Macquarie	0	100,000	Abstain
State Street	97,370	0	For
Bridge Builder Trust	89,518	0	For
MoA Funds Corp	67,022	0	For
QUANTITATIVE MASTER SERIES LLC	64,885	0	For
Brighthouse	12,660	49,735	Abstain

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

4. To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed: Scott Morrison

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 34,225,471WITHHELD: 548,175

Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Scott Morrison”): 34,225,471 for, 548,175 withheld, per its Form 8-K filed 2026-06-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,021,312 outstanding shares: 80% for, 1% withheld (81% of the company cast a for/withheld vote).

The 86 asset managers below cast 100% of the shares they voted on this item FOR (11,557,159 for, 0 against).

FOR 99.8%

FOR: 11,557,159 (99.9%)ABSTAIN: 12,731 (0.1%)

Largest asset managers voting on “To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective” at Tarsus Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	2,105,824	1,851	For
BlackRock	1,588,579	0	For
Fidelity	1,304,608	0	For
Prudential/PGIM	765,639	0	For
JANUS INVESTMENT FUND	738,221	0	For
Lord Abbett	504,366	0	For
Legg Mason	443,209	0	For
Invesco	441,422	0	For
Charles Schwab	329,520	0	For
Waddell & Reed	273,131	0	For
TIAA	267,608	0	For
MFS	261,461	0	For
Loomis Sayles	222,303	0	For
T. Rowe Price	180,401	0	For
DRIEHAUS MUTUAL FUNDS	174,580	0	For
Putnam	147,318	0	For
Allspring	120,498	0	For
Equitable	116,688	0	For
First Trust	110,377	0	For
Delaware/Macquarie	100,000	0	For
State Street	97,370	0	For
Bridge Builder Trust	89,518	0	For
MoA Funds Corp	67,022	0	For
QUANTITATIVE MASTER SERIES LLC	64,885	0	For
Brighthouse	59,141	3,254	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

5. To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed: Wendy Yarno

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 34,398,690WITHHELD: 374,956

Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Wendy Yarno, MBA”): 34,398,690 for, 374,956 withheld, per its Form 8-K filed 2026-06-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,021,312 outstanding shares: 80% for, 0.9% withheld (81% of the company cast a for/withheld vote).

The 86 asset managers below cast 100% of the shares they voted on this item FOR (11,566,635 for, 0 against).

FOR 99.9%

FOR: 11,566,635 (100.0%)ABSTAIN: 3,255 (0.0%)

Largest asset managers voting on “To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective” at Tarsus Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	2,107,674	1	For
BlackRock	1,588,579	0	For
Fidelity	1,304,608	0	For
Prudential/PGIM	765,639	0	For
JANUS INVESTMENT FUND	738,221	0	For
Lord Abbett	504,366	0	For
Legg Mason	443,209	0	For
Invesco	441,422	0	For
Charles Schwab	329,520	0	For
Waddell & Reed	273,131	0	For
TIAA	267,608	0	For
MFS	261,461	0	For
Loomis Sayles	222,303	0	For
T. Rowe Price	180,401	0	For
DRIEHAUS MUTUAL FUNDS	174,580	0	For
Putnam	147,318	0	For
Allspring	120,498	0	For
Equitable	116,688	0	For
First Trust	110,377	0	For
Delaware/Macquarie	100,000	0	For
State Street	97,370	0	For
Bridge Builder Trust	89,518	0	For
MoA Funds Corp	67,022	0	For
QUANTITATIVE MASTER SERIES LLC	64,885	0	For
Brighthouse	59,141	3,254	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

6. TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 38,219,521AGAINST: 3,651

Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm The Company's stockholders approved the ratification of the appointment of Ernst & Young LLP as the Company's i”): 38,219,521 for, 3,651 against, per its Form 8-K filed 2026-06-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,021,312 outstanding shares: 89% for, 0.1% against (89% of the company cast a for/against vote).

The 86 asset managers below cast 100% of the shares they voted on this item FOR (11,566,636 for, 0 against).

FOR 99.9%

FOR: 11,566,636 (100.0%)ABSTAIN: 3,254 (0.0%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at Tarsus Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	2,107,675	0	For
BlackRock	1,588,579	0	For
Fidelity	1,304,608	0	For
Prudential/PGIM	765,639	0	For
JANUS INVESTMENT FUND	738,221	0	For
Lord Abbett	504,366	0	For
Legg Mason	443,209	0	For
Invesco	441,422	0	For
Charles Schwab	329,520	0	For
Waddell & Reed	273,131	0	For
TIAA	267,608	0	For
MFS	261,461	0	For
Loomis Sayles	222,303	0	For
T. Rowe Price	180,401	0	For
DRIEHAUS MUTUAL FUNDS	174,580	0	For
Putnam	147,318	0	For
Allspring	120,498	0	For
Equitable	116,688	0	For
First Trust	110,377	0	For
Delaware/Macquarie	100,000	0	For
State Street	97,370	0	For
Bridge Builder Trust	89,518	0	For
MoA Funds Corp	67,022	0	For
QUANTITATIVE MASTER SERIES LLC	64,885	0	For
Brighthouse	59,141	3,254	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

Largest Tarsus Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked by the number of Tarsus Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 43,021,312 shares outstanding at the time of that meeting.

Top Tarsus Pharmaceuticals, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Janus Henderson	10.70%
2	Deep Track Capital, LP	8.27%
3	RTW INVESTMENTS, LP	7.78%
4	BlackRock	6.89%
5	Vanguard	5.64%
6	Invesco	4.90%
7	Fidelity	4.67%
8	Paradigm Biocapital Advisors LP	4.65%
9	JENNISON ASSOCIATES LLC	3.25%
10	GEODE CAPITAL MANAGEMENT, LLC	2.38%

Reported Tarsus Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Tarsus Pharmaceuticals, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Deep Track Capital, LP	8.37%	13G
BlackRock	8.26%	13F
RTW Investments, LP	7.96%	DEF14A
Paradigm BioCapital Advisors LP	5.67%	DEF14A
Vanguard Group	5.58%	13F
JANUS HENDERSON GROUP PLC	5.21%	13G
Bobak Azamian	5.16%	DEF14A
Morgan Stanley	4.74%	13F
PRUDENTIAL FINANCIAL INC	4.27%	13G
Jennison Associates LLC	3.98%	13G

Percentages above are of 43,021,312 shares outstanding, as reported by Tarsus Pharmaceuticals, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Tarsus Pharmaceuticals, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Tarsus Pharmaceuticals, Inc.'s shareholder meeting held 2026-06-25, in the 2025-2026 proxy season, 292 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,845 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Tarsus Pharmaceuticals, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To hold an advisory vote to approve, on a non-binding basis, our named executive officer… — the reporting funds cast 99.6% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Tarsus Pharmaceuticals, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).